Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Xenon Pharmaceuticals Inc (XENE) NPV

Sell:$9.36 Buy:$9.40 Change: $0.17 (1.84%)
NASDAQ:0.80%
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Sell:$9.36
Buy:$9.40
Change: $0.17 (1.84%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Sell:$9.36
Buy:$9.40
Change: $0.17 (1.84%)
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Contact details

Address:
3650 Gilmore Way
BURNABY
V5G 4W8
Canada
Telephone:
+1 (604) 4843300
Website:
www.xenon-pharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XENE
ISIN:
CA98420N1050
Market cap:
$237.90 million
Shares in issue:
25.78 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Canada
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Tarnow
    Independent Chairman of the Board
  • Ian Mortimer
    President, Chief Financial Officer, Chief Operating Officer
  • Simon Pimstone
    Chief Executive Officer, Director
  • Robin Sherrington
    Executive Vice President - Strategy & Innovation
  • Shelley McCloskey
    Senior Vice President - Human Resources
  • James Empfield
    Senior Vice President - Drug Discovery
  • Ernesto Aycardi-Fonseca
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.